Conference Coverage

VIDEO: Goserelin helps dodge ovarian failure in HR-negative breast cancer


 

AT ASCO 2014

CHICAGO – Adding the gonadotropin-releasing hormone agonist goserelin (Zoladex) to adjuvant or neoadjuvant chemotherapy boosted fertility prospects in premenopausal women with early-stage hormone-receptor–negative breast cancer.

Not only did goserelin reduce by 70% the risk of ovarian failure, a common consequence of chemotherapy, but the monthly injections also offered an intriguing boost in disease-free and overall survival.

Lead author of the intergroup POEMS (Prevention of Early Menopause Study) Dr. Halle Moore of the Cleveland Clinic spoke with us about the late-breaking trial at the annual meeting of the American Society of Clinical Oncology.

Click here to hear more about these practice-changing results.

The study was supported by the National Institutes of Health. Dr. Moore reported no disclosures; three coauthors have financial ties with AstraZeneca, the maker of goserelin.

pwendling@frontlinemedcom.com

Correction 5/31/14: An earlier version of this article carried a headline that misstated the cancer type.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Annual mammography at age 40-59 provides no survival benefit
MDedge Family Medicine
Genomic analyses led to targeted treatment for metastatic breast cancer, though response rate disappointing
MDedge Family Medicine
Whole-genome sequencing not ready for prime time
MDedge Family Medicine
Obesity-hunger paradox prevalent in low-income cancer survivors
MDedge Family Medicine
Postmastectomy radiotherapy improves survival with one to three positive nodes
MDedge Family Medicine
First ASCO survivor care guidelines tackle fatigue, anxiety/depression, neuropathy
MDedge Family Medicine
Topical lidocaine reduces menopausal dyspareunia
MDedge Family Medicine
First SEER analysis including HER2 subtype is reported
MDedge Family Medicine
Obesity increased breast cancer mortality only in premenopausal women
MDedge Family Medicine
Breast cancer fear contributes to prophylactic mastectomy rate
MDedge Family Medicine